Kezdőlap・Részvénylista・Compugen Ltd

Compugen Ltd

Lezárt

2.39 4.37

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.39

Maximum

2.42

Fő mutatók
By Trading Economics
Bevétel	-65M -7.7M
Értékesítés	-65M 2.2M
P/E Szektor átlag	6.263 68.51
Egy részvényre jutó nyereség	-0.07
Profit margin	-352.436
Munkavállalók	75
EBITDA	-64M -7.7M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+107.47% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 9.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	-45M 225M
Előző nyitás	-1.98
Előző zárás	2.39

Compugen Ltd Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 9. 23:52 UTC

Correlated Moves

The US 30Y Treasury Bond Index is trading lower, reaching its lowest point in a month amid cautious market sentiment and correlated asset declines.

2026. aug. 9. 23:51 UTC

Bitcoin and Ethereum decline amid bearish sentiment, while U.S. labor data sparks record highs in equity markets and lowers Fed rate hike expectations.

2026. aug. 9. 23:51 UTC

Singapore's markets closed for National Day; Japan's BOJ releases opinions, while China's inflation and PPI growth fall short of expectations, raising economic stability concerns.

2026. aug. 9. 23:51 UTC

U.S. equity markets rally as disappointing July jobs data lowers Fed rate hike expectations, while Bitcoin and Ethereum decline amid cautious investor sentiment.

2026. aug. 9. 23:51 UTC

Singapore's markets closed for National Day; Japan's monetary policy remains unclear while China's inflation drops to 0.5%, raising deflation concerns.

2026. aug. 9. 23:51 UTC

Retail Sales Ex Autos Expected to Rise 0.2% in July Amid Mixed Economic Signals

2026. aug. 9. 23:51 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.5% Amid Mixed Market Sentiment and Geopolitical Concerns

2026. aug. 9. 23:51 UTC

Japan's GDP Growth Forecasted at 0.02% for Q2 Amid Mixed Economic Sentiment and Global Uncertainties

2026. aug. 9. 23:51 UTC

Correlated Moves

Bitcoin is trading lower during the session, reflecting cautious market sentiment amid slight declines in Ethereum and minimal hedge fund re-grossing in AI themes.

2026. aug. 9. 23:41 UTC

BoJ Summary of Opinions Release Expected to Clarify Interest Rate Outlook Amidst Mixed Market Sentiment and Global Economic Trends.

2026. aug. 9. 23:41 UTC

Japan's June current account data expected to show a significant surplus decline, raising concerns about economic challenges and impacting financial markets.

2026. aug. 9. 23:41 UTC

U.S. Retail Sales Expected to Rise 0.1% in August Amid Cautious Consumer Sentiment and Economic Uncertainty

2026. aug. 9. 23:31 UTC

Market Awaits July 2026 PPI Release Amid Mixed Inflation Signals and Potential Deflationary Pressures.

2026. aug. 9. 23:31 UTC

Correlated Moves

Cardano is declining in today's session, continuing a downward trend observed since Saturday. The asset's movement reflects broader bearish sentiment in the market.

2026. aug. 9. 23:21 UTC

Core Producer Prices Expected to Rise 0.2% Amid Slower Inflation and Cautious Investor Sentiment Ahead of August Release

2026. aug. 9. 23:01 UTC

Palladium is trading lower during Sunday’s session, despite earlier gains. The asset remains above its 20-day moving average and near a one-month high.

2026. aug. 9. 23:01 UTC

Silver has been gaining since Friday's close, currently above its 20-day moving average. The asset reached a session high before pulling back slightly.

2026. aug. 9. 23:01 UTC

Silver/CAD is trading higher since Friday's close, reflecting a cumulative return of 0.17%. The price remains above its 20-day moving average.

2026. aug. 9. 23:01 UTC

Gold/SGD is trading roughly flat, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. aug. 9. 23:01 UTC

Correlated Moves

Gold/NZD is trading higher, reflecting volatility earlier in the session. The asset remains above its 20-day moving average and near its one-month range's upper end.

2026. aug. 9. 23:01 UTC

The US 2Y Treasury Bond Index is trading higher, remaining steady near the upper end of its one-month trading range. No specific news was identified.

2026. aug. 9. 23:01 UTC

Correlated Moves

Gold/JPY is advancing, reflecting a positive trend since Friday's close. The asset remains above its 20-day moving average and near its one-month range high.

2026. aug. 9. 23:01 UTC

Gold and silver are trading lower, continuing a downward trend since Friday's close. The assets briefly rebounded earlier in the session.

2026. aug. 9. 23:01 UTC

Correlated Moves

Gold/GBP is trading roughly flat, influenced by a slight increase in Silver. Market sentiment remains cautious amid minimal hedge fund re-grossing within AI themes.

2026. aug. 9. 23:01 UTC

Silver/NZD is higher today, maintaining a position above its 20-day moving average after pulling back from earlier session highs. No specific news was identified.

2026. aug. 9. 23:01 UTC

Silver/JPY is trading higher today, maintaining a position above its 20-day moving average. The asset showed fluctuations earlier in the session.

2026. aug. 9. 23:01 UTC

Silver/HKD is higher during Sunday’s session, continuing its positive momentum from Friday. The asset remains above its 20-day moving average.

2026. aug. 9. 23:01 UTC

Correlated Moves

Gold/CHF is trading roughly flat, maintaining stability after a slight increase in correlation with silver amid cautious market sentiment and hedge fund activity.

2026. aug. 9. 23:01 UTC

Silver/SGD is advancing during the ongoing session, remaining above its 20-day moving average and near the upper end of its one-month range.

2026. aug. 9. 23:01 UTC

Gold/HKD is trading roughly flat, remaining 6.16% above its 20-day moving average and near the upper end of its one-month range.

Társak összehasonlítása

Árváltozás

Compugen Ltd Előrejelzés

Célár

By TipRanks

107.47% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 5 USD 107.47%

Magas 6 USD

Alacsony 4 USD

3 Wall Street elemző 12 hónapos célárain alapulva a(z)Compugen Ltd termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

3 ratings

Vétel

Tartás

Eladás

3 Wall Street elemző célárain alapulva a(z)Compugen Ltd termékhez az elmúlt 3 hónapban.

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.